R&D channel feed

Sy­ros lays off 35% of work­ers, re­places CEO and los­es CSO af­ter axed pacts

Last year
People

Ex­clu­sive: 'Faster is­n't bet­ter' — Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

Last year
AI

Cor­rect­ed: Syn­dax stops PhI/II leukemia study ear­ly af­ter menin in­hibitor shows ef­fi­ca­cy in chal­leng­ing mu­ta­tion

Last year

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Last year
In Focus

Struc­ture Ther­a­peu­tics 'en­cour­aged' by 5.4% weight loss with its oral GLP-1, plans for more stud­ies

Last year

Bio­nom­ics’ stock sky­rock­ets 340% af­ter PTSD can­di­date pass­es PhI­Ib test

Last year

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Last year

Ger­man ra­dio­phar­ma Ariceum un­veils ear­ly ef­fi­ca­cy sig­nal for lead as­set in neu­roen­docrine can­cers

Last year

Grit­stone inks up to $433M con­tract with BAR­DA for 10,000-per­son Covid-19 vac­cine tri­al

Last year

Biden ad­min­is­tra­tion doles out $100M to re­search drug-re­sis­tant in­fec­tions

Last year

Am­gen read­ies PhI­II tri­al for first Op­di­vo biosim­i­lar, with launch un­like­ly be­fore 2028

Last year

Cor­rect­ed: Cardiff’s stock jumps af­ter shar­ing promis­ing PhII da­ta for its PLK1 in­hibitor in pan­cre­at­ic can­cer

Last year

Gilead stops an­oth­er CD47 study, this time in acute myeloid leukemia

Last year

First shot at pan-coro­n­avirus vac­cine dis­ap­points in VBI Vac­cines study

Last year

Ab­b­Vie drops Cari­bou part­ner­ship on gene-edit­ed CAR-T ther­a­py

Last year
Cell/Gene Tx

Pli­ant shares spike on ex­plorato­ry study re­sults of lead drug in chron­ic liv­er dis­ease

Last year

Io­n­is plans NDA fil­ing for first in­de­pen­dent drug af­ter pos­i­tive da­ta read­out in rare ge­net­ic dis­or­der

Last year

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Last year

Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Last year

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

Last year
Startups

No­var­tis ra­di­oli­gand tri­umphs in a first-line PhI­II tri­al re­cruit­ing pa­tients with rare neu­roen­docrine tu­mors

Last year

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Last year
Deals
Pharma

Mor­phic’s stock falls af­ter new da­ta sug­gest low­er-than-ex­pect­ed ef­fi­ca­cy for its ul­cer­a­tive col­i­tis pill 

Last year

In­di­a's Glen­mark Phar­ma­ceu­ti­cals di­vests 75% stake in its API man­u­fac­tur­ing sub­sidiary

Last year
Manufacturing
First page Previous page 67686970717273 Next page Last page
A service from the Financial Times